A PYMNTS Company

US: Allergan beats Class Certification appeal

By  |  August 5, 2019

The union pension funds claiming Allergan delayed the rollout of generic Asacol will have to wait until the end of trial-level proceedings to challenge the denial of their renewed bid for class certification.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The US Court of Appeals for the First Circuit rejected the petition for a mid-case appeal by the pension funds. Their antitrust lawsuit accuses Allergan of reaching “reverse payment” patent settlements with Zydus Pharmaceuticals USA and its parent Cadila Healthcare over Asacol, a colitis drug. The lawsuit also claims Allergan and Warner Chilcott engaged in “drug hopping.”

    The original Asacol was a 400-milligram tablet that treated two digestive-tract ailments, colitis, and Crohn’s disease. It had been brought to market by Warner Chilcott, a company bought by Actavis 3 in 2013, and was its biggest drug, with sales of US$891 million in 2012. In the spring of 2013, just as the patent was about to expire, Warner Chilcott/Actavis discontinued Asacol and came out with Dezicol, followed by Asacol HD. They both had the same basic ingredient; the only difference was that Dezicol came in capsule form, while Asacol HD was an 800-milligram version.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.